Serum institute Covovax first Indian COVID vaccine to be sold in Europe: Adar Poonawalla

Calling it an "important milestone, the CEO said, "We hope that in future other vaccines made in India will also be accepted and used in Europe.

Published On 2022-04-13 06:22 GMT   |   Update On 2024-02-16 07:05 GMT
Advertisement

New Delhi: Chief Executive Officer (CEO) of Serum Institute of India (SII) Adar Poonawalla on Tuesday informed that the company has exported nearly 40 million COVID vaccine doses to European countries and Australia, and said that the Covovax is the first vaccine made in India to be sold in Europe.

Poonawalla, in an exclusive interview with ANI, said, "We have a stockpile of 200 million doses of Covishield
Advertisement
...We've already exported 40 million doses of Covovax to European countries, Australia. It's for the first time that a vaccine made in India is sold in Europe."
Calling it an "important milestone, the CEO said, "We hope that in future other vaccines made in India will also be accepted and used in Europe."
Meanwhile, the Covovax has been approved by the Drugs Controller General of India (DCGI) for children above 12 years of age, but its administration has not been allowed yet.
To this, Poonawalla said, "Covovax will be used for children. It has been approved by DCGI and we're waiting for the Government of India to allow us to put it on the CoWIN app to make it available to everyone."
If it's taken in the government program also, then the SII will charge the same price of Rs 225 even for the private market, he informed.
When asked about the mix-and-match trials of COVID vaccines such that Covovax is used as a booster, Poonawalla said that SII has been asked to conduct a study on that.
"We will do that trial. Covovax, in about two or three months, can also be made available as a booster. But at the moment, it is approved for children of the age of 12 and above," he said.
Poonawalla has also requested the Centre to reduce the gap between the second and the third dose of the COVID vaccine to six months from the existing nine.
"The (vaccine inoculation) uptick right now is a bit slow...because we have got this rule that you have to wait for nine months between dose two and three. We have appealed to the govt on how to reduce this further to six months, will propose the six-month gap," he said. 

Read also: CDSCO panel seeks additional data on Serum Institute EUA application for Covovax use in 7-11 year-olds

Tags:    
Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News